Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients

Journal of Viral Hepatitis

Volumn 17, Issue 10, 2010, Pages 714-719

  Pineda, J A ^a   Gonzalez J ^b   Ortega, E ^c   Tural, C ^d   MacIas J ^a   Griffa, L ^e   Burgos, A ^e  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e ABBOTT LABORATORIES   (Spain)

Author keywords

hepatitis C; HIV; liver fibrosis; transient elastometry

Indexed keywords

ALCOHOL; CD4 ANTIGEN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DISEASE DURATION; ELASTOGRAPHY; FEMALE; GENOTYPE; GROUPS BY AGE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77956635100     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01229.x     Document Type: Article

References (24)

1. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999 30: 1054 1058. (Pubitemid 29458296)
2. Tural C, Fuster D, Tor J et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003 10: 118 125.
3. Mariné-Barjoan E, Saint-Paul MC, Pradier C et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004 18: 2163 2170.
4. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001 34: 283 287.
5. Martín-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004 38: 128 133.
6. Bräu N, Salvatore M, Ríos-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006 44: 47 55.
7. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus coinfected patients? Clin Infect Dis 2006 42: 262 270.
8. Macías J, Mira JA, López-Cortés LF et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006 11: 839 846.
9. Berenguer J, Bellón JM, Miralles P et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008 46: 137 143.
10. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97: 2614 2618.
11. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008 48: 835 847.
12. de Lédinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/Hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006 41: 175 179.
13. Vergara S, Macías J, Rivero A et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfeciton. Clin Infect Dis 2007 45: 969 974.
14. Tural C, Ortega E, Pineda JA, González-García J, Burgos A, Cabrero E. Cross-sectional study to determine prevalence of significant liver fibrosis (F2-F4) in HIV-HCV coinfected patients. 9th International Congress on Drug Therapy in HIV Infection. Glasgow, UK: GRAFIHCO study. 9-13 November 2008. Abstract P264.
15. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20: 15 20.
16. Macías J, Recio E, Vispo E et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV-coinfected patients. J Hepatol 2008 49: 916 922.
17. Castellares C, Barreiro P, Martín-Carbonero L et al. Liver cirrhosis in HIV infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008 15: 165 172.
18. Massard J, Ratziu V, Tabut D et al. Natural history and predictors of disease in chronic hepatitis C. J Hepatol 2006 44: S19 S24.
19. Merchante N, Girón-González JA, González-Serrano M et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006 20: 49 57.
20. Bonacini M, Louie S, Bzowej N, Rock Wohl A. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004 18: 2039 2045.
21. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003 362: 1708 1713.
22. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero de 2009). http://www.gesida.seimc.org/ pcientifica/dcconsensos.asp?apnv0=pcientifica&apnvA=dcconsensosyrc& appag=dcconsensos-txt.htm.
23. Clumeck N, Pozniak A, Raffi F EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008 9: 65 71.
24. Pineda JA, García-García JA, Aguilar-Guisado M et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007 46: 622 630.